Polyaldehyde cross-linker minimizes the inflammatory response associated with glutaraldehyde-based sealants1,3
Minimal swelling (<10%) with application4
Reducing potential impact on surrounding anatomic structures that may be sensitive to compression2
Noncytotoxic and bioresorbable3
Please see Important Risk Information for complete safety information.
Established safety profile
Randomized, controlled study: PREVELEAK was associated with a significantly lower cumulative incidence of adverse events (AEs) within 6 weeks post treatment compared with Gelfoam Plus1,5
Safety: Complications at 6 weeks
The overall incidence of serious individual AEs within 6 weeks post treatment did not differ between treatment groups1
Stone et al: In a randomized, multicenter comparative study of 331 anastomotic sites in 217 patients undergoing vascular reconstruction surgeries (aortic, extremity bypass, carotid, hemodialysis access, or other), suture lines were sealed with either PREVELEAK or Gelfoam Plus.5
Scroll down for Indications and Important Risk Information
PREVELEAK® Surgical sealant is indicated for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.
Important Risk Information
Not for use in patients with known allergies to materials of bovine or shellfish origin.
Not for intravascular use.
Not for cerebrovascular repair or cerebrospinal leak repair.
Warnings and Precautions
Do not use as a substitute for sutures or staples.
Avoid exposure to nerves.
Do not use in the presence of obvious infection and use with caution in contaminated areas of the body.
Do not allow either the uncured or polymerized form to contact circulating blood.
PREVELEAK contains a material of animal origin that may be capable of transmitting infectious agents.
Repeated use of PREVELEAK in subsequent surgeries has not been studied.
Hypersensitivity reactions were not seen using PREVELEAK, but hypersensitivity of BSA has been reported.
Avoid contact with skin or other tissue not intended for application.
Safety and effectiveness of PREVELEAK in minimally invasive procedures or coronary artery bypass grafting (CABG) have not been established.
Do not use blood saving devices when suctioning excess PREVELEAK from the surgical field.
PREVELEAK syringe and delivery tips are for single patient use only. Do not resterilize.
Do not use if packages have been opened or damaged.
Take care not to spill contents of syringe. Avoid tissue contact with material expelled from delivery tip during priming.
Avoid pausing more than 10-15 seconds between priming and application to prevent polymerization within the delivery tip.
Minimize use in patients with abnormal calcium metabolism (e.g. chronic renal failure, hyperparathyroidism). Polyaldehyde treated tissue can have an enhanced propensity for mineralization.
Evidence of cytotoxicity was observed during cell culture-based laboratory assays and is believed to be due to the polyaldehyde component of the product. No evidence of cytotoxicity was observed in animal or clinical studies.
Potential adverse effects associated with the use of this class of surgical sealants include application of the sealant to tissue not targeted for the procedure, failure of the sealant to adhere to the tissue, hypersensitivity reaction such as swelling or edema at the application site, possible transmission of infectious agents from materials of animal origin, thrombosis and thromboembolism.
Serious adverse events that occurred in clinical studies included death, hypotension, thrombosis/thromboembolism, ischemia, respiratory failure/dysfunction, steal syndrome, and myocardial infarction.
Use In Specific Populations
Use of PREVELEAK in pediatric or pregnant patients has not been studied.
To report SUSPECTED ADVERSE REACTIONS, contact Mallinckrodt Hospital Products, Inc. at 1-800-778-7898 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see the complete Instructions for Use here.
To report SUSPECTED ADVERSE REACTIONS, contact Mallinckrodt Hospital Products, Inc. at 1-800-778-7898.
References: 1. PREVELEAK Surgical sealant [instructions for use]. Hazelwood, MO: Mallinckrodt Hospital Products Inc; 2016. 2. Tenaxis Medical, Inc. Clinical evaluation report for ArterX Surgical Sealant. April 22, 2013. 3. Florek H-J, Brunkwall J, Orend K-H, Handley I, Pribble J, Dieck R. Results from a first-in-human trial of a novel vascular sealant. Front Surg. 2015;2:29. doi:10.3389/fsurg.2015.00029. 4. Tenaxis Medical, Inc. Summary of safety and effectiveness: ArterX Surgical Sealant. March 1, 2013. 5. Stone WM, Cull DL, Money SR. A randomized prospective multicenter trial of a novel vascular sealant. Ann Vasc Surg. 2012;26(8):1077-1084.
The information on this site is intended for US health care professionals only.